Price (delayed)
$41.97
Market cap
$2.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.92
Enterprise value
$2.31B
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which
There are no recent dividends present for CLDX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.